Drug intelligence / Profile preview

copper-64 CANF

Development stage: Phase 1
Lead developer: Clarity Pharmaceuticals
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Copper-64 CANF (Cu-CANF) is a radiopharmaceutical that combines the copper-64 radioisotope with a targeting molecule (CANF). Copper-64 has a half-life of 12.7 hours and emits both positron (β+, 18%) and beta (β-, 39%) particles, making it suitable for both PET imaging and targeted radiotherapy. The 12.7-hour half-life allows for centralized production and distribution to remote imaging centers, providing logistical advantages over shorter-lived radioisotopes like gallium-68 or fluorine-18.

Other names: 64Cu-CANF

Targets

NPR3 (Natriuretic peptide receptor C)

Beyond the preview

Go deeper on copper-64 CANF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on copper-64 CANF.

Explore the full profile